P>In the March 6 issue of Medical Device Daily, it was reported that St. Jude Medical (St. Paul, Minnesota) was the first company to enroll patients in a U.S. clinical trial to evaluate the connection between patent foramen ovales (PFOs) and migraine headaches. In fact, NMT Medical (Boston) was the first company to begin U.S. enrollment in a PFO/migraine trial, with its 600-patient MIST II (Migraine Intervention with STARflex Technology), reporting first enrollment in early January, according to a company press release dated Jan. 11 but not previously reported in MDD.

No Comments